Chapter 2: Pharmacological Principles – Pharmacokinetics, Dynamics & Therapeutics

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to The Deep Dive.

Today we're really undertaking an essential journey.

We're looking into the fundamental rules of chemistry and biology that, well, they govern safe medication use, the core principles of pharmacology.

That's right.

Pharmacology, it's the really broad science of drugs,

basically any chemical that affects physiological processes.

And our mission today.

Our mission in this Deep Dive is to kind of synthesize the three big phases of drug activity, that's pharmaceutics, pharmacokinetics, and pharmacodynamics.

We want to give you the critical insights you need for clinical practice without getting too bogged down in endless definitions.

Okay, so before we even get into the process itself, let's quickly nail down the nomenclature, because drugs have three names, right, and they serve different purposes.

You've got the really long, complex chemical name, describes the molecular structure.

Yeah, very technical.

And then importantly, there's the generic name.

This is the simpler non -proprietary one.

It's used in official drug lists,

universally recognized.

And finally, the trade name.

That's the proprietary one, the brand name, trademarked, marketed by a specific company.

Think ibuprofen.

That's the generic name.

Right, but the trade names are Advil or Motrin.

Exactly.

And knowing that generic name is just paramount because, well, the active ingredient is the same no matter what the box looks like.

Okay, so once that pill is identified and swallowed, we hit phase one,

pharmaceutics.

Pharmaceutics.

Yeah, this is basically the study of how the drug's physical form, the dosage form, influences how the body eventually responds.

It's all about the preparation, really.

And preparation starts with dissolution.

That's the solid drug disintegrating, right, becoming soluble in the digestive fluid so it can actually be absorbed.

Absolutely.

And what's fascinating here, as you mentioned, is how that dosage form completely dictates the absorption timeline.

How so?

Well, think of it like a speed test.

Liquid -formed syrups, elixirs, they're the fastest.

They skip that whole disintegration step because, well, they're already dissolved.

Makes sense.

But on the other end, you have things like enteric -coated tablets.

There's a slowest.

Their coating is specifically designed to stop breakdown in the stomach's acid.

Ah, so they wait until the intestines.

Precisely.

They delay absorption until they reach the more alkaline environment of the intestines.

Okay, and here's where clinical safety gets really intense.

We have time release technology.

You see those abbreviations, SR, CR, XL.

Sustain release, controlled release, extended release.

Yeah, designed to prolong the drug's action, releasing it slowly over hours.

And this is just a critical point for anyone administering meds.

You must not crush or chew extended release or enteric -coated forms.

Why is that so crucial?

Because if you drake that coating, you destroy the pharmaceutical design.

You cause an immediate, accelerated release of the entire dose all at once.

Which could be dangerous.

Extremely.

Imagine doing that with an extended release opioid painkiller.

That sudden flood could easily lead to acute toxicity, maybe even respiratory depression.

It bypasses the whole point of the slow release.

We should also quickly mention those newer methods, the ones that bypass the stomach, like thin -film drug delivery.

Oh yeah, the wafers or orally disintegrating tablets.

They get absorbed directly through the oral mucosa, under the tongue, or against the cheek.

Quick absorption there too.

Okay, so once the drug is dissolved and ready, we move to the main event, pharmacokinetics.

Right, kinetics.

This is the drug's journey through the body.

It's defined by four key steps.

Absorption, distribution, metabolism, and excretion.

The ADME framework.

ADME.

And this framework determines the crucial time points, onset, peak, and duration of the drug's effect.

Exactly.

So let's start with A, absorption, movement from where it's given into the bloodstream, how much actually makes it in.

We measure that using bioavailability.

It's basically the percentage of the administered dose that reaches the systemic circulation unchanged.

And VIVEU drugs.

VIVEU drugs are the benchmark.

Their bioavailability is 100 % because while you're putting them directly into the vein, every single molecule gets into the circulation immediately.

But oral drugs face a hurdle, don't they?

The first pass effect, or FPE.

Could you explain that?

Sure.

So when you take a drug orally, it gets absorbed from the GI tract, but then it travels through the portal vein directly to the liver before it reaches the rest of the body.

The systemic circulation.

And the liver is the main site for drug metabolism.

Exactly.

So if the liver rapidly metabolizes a large chunk of that drug into inactive forms during this first pass, then the amount of drug that actually makes it out to the target tissues is significantly reduced.

Its bioavailability is much lower than 100%.

Which explains why oral doses often need to be much larger than IV doses for the same medication, right?

To get the same effect.

Precisely.

Think about furosemide, the diuretic.

Given the feed, it bypasses the FPE entirely, works in about five minutes, 100 % available.

The oral dose takes maybe an hour to start working, and the IV dose is always smaller because none of it is lost on that first pass through the liver.

That's a really clear example, and it highlights why you absolutely cannot just change the prescribed route.

Never.

The dosing is route specific.

It's also why some critical meds, like nitroglycerin for chest pain, are given sublingually under the tongue.

Ah, another way to bypass the liver first pass.

Right.

Absorbed directly into the bloodstream from the oral mucosa.

Ensures rapid action and high bioavailability when you really need it.

Okay, makes sense.

So assuming the drug is absorbed.

Step two is D, distribution.

Transport out of the blood to the site of action.

Where does it go first?

Well, it travels fastest to the areas with the best blood supply.

I think heart, liver, kidneys, brain, those get flooded first.

It's slower to get into areas like muscle, skin, and fat.

But there's a critical concept here within distribution,

protein binding.

Yes, very important.

Drugs, once in the bloodstream, tend to bind to proteins, mainly albumin.

Picture albumin molecules like little taxi cabs circulating in the blood.

So the drug hops onto the albumin.

Some of it does, but here's the key.

Only the drug molecules that are not bound to free drug are pharmacologically active.

Only the free drug can leave the bloodstream and reach the tissues to exert an effect.

The bound portion is just riding around.

Temporarily inactive, yeah.

It acts like a reservoir.

As free drug leaves the circulation to go to the tissues, some of the bound drug gets released from the albumin to maintain equilibrium.

Okay, so this is where drug interactions can get really tricky.

If a patient is taking two drugs that are both highly protein bound.

They compete.

They fight for those limited binding sites on the albumin molecules.

And if one drug bumps the other off.

Then you suddenly get a higher concentration of free active drug of the one that got bumped off.

This can unexpectedly increase the more active drug available than anticipated.

That's a major risk.

And we also have physical barriers, right?

Like the blood brain barrier.

Absolutely.

The BBB is very selective, protects the brain, makes it tough for many drugs to get into the central nervous system.

Which is a challenge, for instance, when treating brain infections.

All right.

ADME.

Next is M metabolism, also called biotransformation.

The body starts changing the drug chemically.

Where does this mainly happen?

Primarily in the liver.

That's the main metabolic powerhouse.

The goal is usually to alter the drug, making it inactive or converting it into a more polar water soluble compound.

Why water soluble?

To make it easier for the kidneys to excrete it later on.

Sometimes, though, metabolism actually activates a drug.

If the original drug was inactive, it's called a pro drug and the liver turns it into its active form.

And the engine driving this whole process is the cytochrome P450 enzyme system.

Yes, the P450 system.

It's a large family of enzymes, mainly in the liver.

They are absolutely critical, especially for metabolizing lipid soluble drugs, drugs that like fatty environments.

And this system is another major site for drug interactions.

Huge.

Because other drugs, or even foods, can affect these P450 enzymes.

We generally talk about two main effects.

Enzyme inhibition and enzyme induction.

Okay, let's take inhibitors first.

Enzyme inhibitors are drugs that decrease the activity of P450 enzymes,

or slow down the metabolism of other drugs processed by that same enzyme.

So if metabolism slows down?

The drug that's being affected hangs around longer, accumulates in the body.

This increases the risk of toxicity because levels get too high.

And the opposite would be inducers.

Right.

Enzyme inducers stimulate P450 enzyme activity.

They speed up metabolism.

Meaning the affected drug gets cleared out faster?

Much faster.

Which leads to decreased pharmacological effect.

The drug might not work effectively, or at all, because it's being eliminated too quickly.

Therapeutic failure.

Grapefruit juice is a classic inhibitor, isn't it?

It is.

A well -known inhibitor of certain P450 enzymes.

Can cause dangerous accumulation of some medications, like certain statins or calcium channel blockers.

So this really underscores why things like liver disease are so significant if the liver isn't working well.

You absolutely must anticipate altered metabolism.

Drug accumulation is a major risk, and doses often need to be reduced significantly.

Age, genetics, other diseases, they all impact metabolic capability too.

Okay, ADME wraps up with Ease Excretion.

Getting the drug out of the body.

Primarily the kidney's job.

They filter the blood, reabsorb some things, actively secrete others into the urine.

And since the liver usually makes drugs more water -soluble during metabolism, that makes it easier for the kidneys to filter them out and excrete them in urine.

Are there other routes?

Oh yes.

The liver and bowel are important too.

Drugs can be excreted into bile by the liver, then eliminated in the feces.

That's biliary excretion.

And there's something called enterohepatic recirculation.

Right.

That's a bit more complex.

A drug is excreted in bile, enters the intestine, but then gets reabsorbed from the intestine back into the bloodstream, goes back to the liver, and the cycle can repeat.

So it sticks around much longer.

Significantly longer.

It prolongs the drug's half -life and duration of action.

This means you need to monitor for effects, even potential toxicity, potentially for days after the initial dose, because it keeps cycling back.

Okay, so we've walked through ADME, how the body handles the drug.

Now let's look at the timing.

The pharmacokinetic time points.

The most fundamental measure seems to be half -life.

Half -life.

It's simply the time it takes for the concentration of the drug in the blood to decrease by 50 percent.

And why is that so important?

It dictates the dosing schedule.

It determines how long it takes to reach steady state.

Steady state B.

That's the physiological plateau,

where the amount of drug being eliminated equals the amount being absorbed with each dose.

You've got consistent drug levels in the body.

And reaching that takes about...

Typically about four to five half -lives.

Once you're at steady state, you generally have consistent therapeutic effects.

Then we have the points on the drug effect curve.

Onset, peak, and duration.

Right.

Onset of action is the time it takes for the drug to produce a therapeutic response.

Peak effect is the time to reach the maximum response.

And duration of action is how long that response lasts at a sufficient level.

And this curve defines the therapeutic window, doesn't it?

The safety margin.

Exactly.

That window lies between the minimum effective concentration needed and the level where toxicity starts.

It's often monitored using peak and trough levels.

Peak level being the highest concentration, usually measured after the dose.

Right.

Indicating the risk of toxicity.

And trough level is the lowest concentration, usually measured just before the next dose.

Indicating the risk of the drug level falling too low, becoming subtherapeutic.

Correct.

Measuring these is therapeutic drug monitoring, or TDM.

Essential for drugs with a narrow therapeutic window, where the line between effective and toxic is very thin.

Okay, so that covers kinetics, what the body does to the drug.

This brings us to the final phase, pharmacodynamics.

Dynamics.

Now we flip it.

This is about what the drug does to the body.

The relationship between the drug concentration and the actual pharmacological response.

The therapeutic effect we want.

How do drugs actually work?

What are the basic mechanisms?

Well, the most common way is through receptor interactions.

Think of it like a lock and key.

The drug molecule, the key, binds to a specific receptor site, the lock, on a cell surface or inside a cell.

And what happens when it binds?

If the drug binds and stimulates a response, mimicking or enhancing the body's natural processes, it's called an agonist.

Like turning the key and opening the lock.

Pretty much.

But if the drug binds to the receptor and blocks a response,

preventing the body's natural key from fitting,

it's an antagonist or an inhibitor.

Like putting the wrong key in the lock so the right one can't get in.

Exactly.

It occupies the site without activating it.

And there's nuance, too.

Things like partial agonists exist, which bind and cause some response, but less than a full agonist.

Allows for fine tuning.

Okay, so receptors are one way.

What else?

Drugs can also work through enzyme interactions.

They might inhibit an enzyme's action, which is more common, or sometimes enhance it.

It's a selective interaction with that specific enzyme.

And the third way.

Non -selective interactions.

These drugs don't target specific receptors or enzymes.

Instead, they act through more general physical or chemical means.

Maybe disrupting cell membranes or cellular processes.

Some cancer drugs and antibiotics work this way.

Got it.

Now maybe we can put these actions into context with pharmacotherapeutics, the different reasons we use drugs.

Sure.

It's helpful to think about the goal of the therapy.

Is it acute therapy for life -sustaining needs in critical illness?

Like emergency blood pressure meds?

Right.

Or maintenance therapy to prevent progression of a chronic condition, like hypertension meds you take daily.

Supplemental therapy replaces something the body lacks, like insulin for diabetes.

What about palliative care?

Palliative therapy focuses on comfort and symptom relief, not cure.

Supportive therapy helps maintain body functions during recovery from illness.

Propylactic therapy aims to prevent illness, like vaccines or pre -surgery antibiotics.

And empirical therapy.

That's treating based on high clinical probability of a certain condition before diagnostic results are confirmed.

Like starting antibiotics for suspected pneumonia based on symptoms.

Okay, let's shift back to safety.

You mentioned the therapeutic window.

How do we quantify that safety margin?

We use the Therapeutic Index, TI.

It's the ratio comparing the drug dose that causes toxicity to the dose that produces the therapeutic effect.

So a high TI means?

A high or wide TI means there's a large gap between the effective dose and the toxic dose.

The drug is relatively safe.

But a low or narrow TI, I think warfarin, digoxin, lithium, means that gap is small.

And for the learner, a low TI means?

It means close monitoring is absolutely essential.

Blood tests, watching for side effects.

Because even small changes in dose or patient condition can push the drug level from therapeutic into toxic territory very easily.

We also need to distinguish tolerance from dependence.

Yes.

Tolerance is when you need increasingly larger doses over time to get the same effect.

The body adapts.

Dependence is different.

It's a physiological or psychological need for the drug to avoid withdrawal symptoms or maintain a sense of well -being.

They often occur together but aren't the same thing.

And drug interactions, again, how do we categorize the effects when drugs are combined?

We can see additive effects where 1 plus 1 equals 2.

Two drugs with similar actions just add their effects together.

Then there are synergistic effects.

Synergy is when 1 plus 1 is greater than 2.

The combined effect is much larger than the sum of their individual effects.

This is often used intentionally like combining different types of blood pressure meds for a better outcome.

And the opposite.

Antagonistic effects, where 1 plus 1 is less than 2.

One drug reduces or cancels out the effect of another.

A big concern, for example, is when antacids block the absorption of antibiotics like ciprofloxacin, making the antibiotic less effective.

And one more, incompatibility.

That's specific to mixing parenteral injectable drugs.

It's a physical or chemical reaction.

Often you see a precipitate cloudiness, meaning the drugs have deteriorated when mixed.

You absolutely cannot administer that mixture.

Okay, finally, let's talk about when things go wrong.

Adverse events.

How do we differentiate the terms?

It's important.

An adverse drug event, ADE, is kind of the umbrella term, any undesirable occurrence involving medication use.

But a medication error, EA, is a preventable mistake in that process.

Wrong drug, wrong dose, wrong route.

And the adverse drug reaction, ADR.

An ADR is different.

It's an unexpected, undesirable reaction that occurs at therapeutic doses.

It's usually related to the drug's properties or the patient's individual response, not an error in administration.

And knowing the difference matters because?

Because an ME means we need to fix the system or process to prevent it from happening again.

An ADR might require changing the dose, stopping the drug, or managing the reaction itself.

It's about patient factors more than system errors.

What are the types of ADRs?

Well, there are pharmacological reactions, which are basically an extension of the drug's normal effect, just too much of it.

Like blood pressure dropping too low from an anti -hypertensive, predictable dose -related.

And allergic reactions.

Yes.

Allergic reactions involve the immune system hypersensitivity.

Can range from a rash to life -threatening anaphylaxis, involves histamine release.

Unpredictable, unless the patient has a known allergy.

And the really unpredictable ones.

Those are the idiosyncratic reactions.

Unexpected, peculiar to that specific patient,

often due to underlying genetic differences in how they handle the drug.

Which brings us back to pharmacogenetics.

Exactly.

A key example is G6PD deficiency.

It's an enzyme deficiency more common in people of African, Middle Eastern, or South Asian descent.

If they lack this enzyme and are exposed to certain drugs, like some anti -malarials or sulfa drugs, it can cause the red blood cells to break down hemolysis.

So genetics can dramatically alter drug response.

Absolutely.

It highlights that drug therapy is becoming increasingly personalized.

We should also briefly touch on those really high -risk toxic effects.

Right.

We need to be aware of teratogenic effects, drugs that cause structural defects in a developing fetus.

The most vulnerable period is usually weeks 3 through 12 of gestation.

Mutagenic and carcinogenic.

Mutagenic effects cause permanent changes in the genetic material, DNA.

Carcinogenic effects are those that cause cancer.

These are obviously major concerns with certain drug classes.

And if an overdose does happen, toxicology principles guide the response.

Yes, the study of poisons.

In clinical toxicology, the absolute priority is always the ABC's airway breathing circulation.

Stabilize the patient first.

Then, focus on preventing further absorption of the drug, like using activated charcoal where speeding up its elimination.

And knowing specific antidotes is crucial.

Non -negotiable for emergency situations.

Things like naloxone, Narcan for opioid overdose, or acetylcysteine for acetaminophen, Tylenol overdose.

Having those readily available can be life -saving.

Okay, so we have really covered the essential framework today.

Pharmaceutics, the dosage form matters.

Pharmacokinetics, ADME, the body's handling.

And pharmacodynamics, what the drug actually does, plus all the critical safety concepts.

I think the takeaway for you, the learner, is the power of anticipation.

If you truly understand ADME, especially how a drug is metabolized and excreted, you can start to predict potential problems.

Like in patients with liver or kidney issues.

Exactly.

You can anticipate drug accumulation,

increase risk of toxicity, and know that dose adjustments are likely necessary before problems arise, or before the lab results even confirm organ dysfunction.

That ability to anticipate, to foresee clinical danger based on these principles, really is the core of providing safe, high -quality patient care.

It truly is.

Understanding the why behind drug actions and patient responses makes all the difference.

Well, thank you for joining us for this deep dive into these foundational pharmacological principles.

We hope this helps clarify these crucial concepts, and we wish you the very best in your studies.